Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.82 |
| ▸ | PGR | P06401 | 4/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | AR | P10275 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | IKBKB | O14920 | 1/20 | 0.82 |
| ▸ | CHUK | O15111 | 1/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.82 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.82 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.82 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL2940262 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Betamethasone SCHEMBL29047992 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL2933295 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25246105 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL93889 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25253296 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25248831 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25292805 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL5151472 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25247721 | 0.99 | NR3C1 (0.83) | NR3C1CYP3A4HIF1AHSD17B10PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993715-B1 | IMPLANTATION NEEDLE FOR INSERTING A SUBCUTANEOUSLY INSERTABLE ELEMENT INTO A BODY TISSUE | HOFFMANN LA ROCHE (CH) | 2024-04-17 | — | — | EP | claimed |
| US-20230320979-A1 | OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION | SANTEN SAS (FR) | 2023-10-12 | — | — | US | claimed |
| EP-4213804-A1 | OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION | Santen SAS (FR) | 2023-07-26 | — | — | EP | claimed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-116367824-A | Oil-in-water emulsion for intravitreal administration | 桑腾股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| WO-2022058325-A1 | OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION | SANTEN SAS (FR) | 2022-03-24 | — | — | WO | claimed |
| EP-2914311-B1 | METHOD OF TREATING VASCULAR DISEASE IN DIABETIC PATIENTS | ABBOTT CARDIOVASCULAR SYSTEMS INC (US) | 2017-06-28 | — | — | EP | claimed |
| EP-2914311-A1 | METHOD OF TREATING VASCULAR DISEASE IN DIABETIC PATIENTS | Abbott Cardiovascular Systems Inc. (US) | 2015-09-09 | — | — | EP | claimed |
| US-9060923-B2 | Method of treating vascular disease in diabetic patients | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-20140127278-A1 | Method Of Treating Vascular Disease In Diabetic Patients | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-05-08 | — | — | US | claimed |
| WO-2014070322-A1 | METHOD OF TREATING VASCULAR DISEASE IN DIABETIC PATIENTS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-05-08 | — | — | WO | claimed |
| US-8623852-B2 | Topical methods and compositions for the treatment of eye diseases and conditions | SANTEN SAS (FR) | 2014-01-07 | — | — | US | claimed |
| US-20130303496-A1 | Method Of Treating Vascular Lesions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2013-11-14 | — | — | US | claimed |
| EP-2564853-A1 | Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders | Novagali Pharma S.A. (FR) | 2013-03-06 | — | — | EP | claimed |
| US-20100286065-A1 | TOPICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES AND CONDITIONS | NOVAGALI PHARMA SA (FR) | 2010-11-11 | — | — | US | claimed |
| EP-2229174-A1 | COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS | Novagali Pharma S.A. (FR) | 2010-09-22 | — | — | EP | claimed |
| WO-2009071594-A1 | COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS | NOVAGALI PHARMA SA (FR) | 2009-06-11 | — | — | WO | claimed |
| US-20240358829-A1 | Lymphocyte Population and Methods for Producing Same | AVM BIOTECHNOLOGY, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20070280995-A1 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye | NOVAGALI PHARMA SA (FR) | 2007-12-06 | — | — | US | disclosed |
| WO-2007138113-A1 | USE OF A STEROID PRODRUG FOR THE TREATMENT OF DISEASE OF THE POSTERIOR SEGMENT OF THE EYE | NOVAGALI PHARMA SA (FR) | 2007-12-06 | — | — | WO | disclosed |